Company profile: Ceregene

1.1 - Company Overview

Ceregene

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of AAV-based gene therapies delivering neurotrophic growth factors to treat neurodegenerative and ocular diseases. Pipeline includes CERE-120 for Parkinson’s, CERE-110 for Alzheimer’s, CERE-130 for ALS, and CERE-140 for retinitis pigmentosa and age-related macular degeneration. Proprietary AAV vectors target degenerating neurons; clinical programs include Phase 2 trials for Parkinson’s and planning for Alzheimer’s.

Products and services

Gene Delivery Technology: Proprietary AAV-based system delivering genes encoding neurotrophic factors to degenerating neurons, supplying long-term therapeutic benefits for major neurodegenerative disorders
CERE-120: Gene therapy product containing the neurturin (NTN) gene that promotes survival and function of dopamine motor neurons in Parkinson's disease, Phase 2
CERE-110: AAV2-based vector expressing nerve growth factor (NGF) engineered to protect and restore cholinergic neurons for treating Alzheimer's disease, entering Phase 2 studies

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Ceregene

Algynomics

HQ: United States Website

Description: Provider of a research-stage pain diagnostics platform leveraging patient cohorts to deliver prospective data that identifies individuals at increased risk for chronic pain, enabling targeted preventive efforts and enhancing patient stratification in clinical trials to identify treatment responders.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Algynomics company profile →

Rapport Therapeutics

HQ: United States Website

Description: Provider of precision medicines for neurological disorders, leveraging a RAP Technology Platform to discover and develop small-molecule therapies targeting specific neuronal receptor complexes. Programs include TARPγ8 AMPAR small molecules in clinical development for epilepsy with potential in pain and bipolar disorder, and discovery-stage nAChR modulators for chronic pain and hearing disorders.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Rapport Therapeutics company profile →

Pacira BioSciences

HQ: United States Website

Description: Provider of specialty pharmaceutical products and pain management technologies, including EXPAREL, a local anesthetic used during surgery to manage pain and reduce opioid use; ZILRETTA, an extended-release injectable for osteoarthritis knee pain; ioveraº, a cryoanalgesia system delivering immediate relief; and pMVL, a multivesicular liposome drug delivery technology.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Pacira BioSciences company profile →

Satsuma Pharmaceuticals

HQ: United States Website

Description: Provider of clinical-stage biopharmaceutical development for migraine, advancing STS101, a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine (DHE) for the acute treatment of migraine, self-administered via a pre-filled, single-use nasal delivery device.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Satsuma Pharmaceuticals company profile →

Neuraxpharm

HQ: Germany Website

Description: Provider of branded and generic CNS pharmaceuticals and nutraceuticals in main European countries, developing and commercializing products for CNS disorder prevention and treatment. Develops and manufactures finished dosage forms (mainly solid oral) for CNS and other areas; includes Buccolam for acute pediatric seizures and Preventan for immune support. Also offers LepsiApp for epilepsy management, R&D (actives, bioequivalence, regulatory), and pharmacovigilance.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Neuraxpharm company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Ceregene

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Ceregene

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Ceregene's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Ceregene's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Ceregene

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Ceregene's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Ceregene's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Ceregene

4.2 - Public trading comparable groups for Ceregene

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Ceregene

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Ceregene

What does Ceregene do?

Ceregene is a provider of AAV-based gene therapies delivering neurotrophic growth factors to treat neurodegenerative and ocular diseases. Pipeline includes CERE-120 for Parkinson’s, CERE-110 for Alzheimer’s, CERE-130 for ALS, and CERE-140 for retinitis pigmentosa and age-related macular degeneration. Proprietary AAV vectors target degenerating neurons; clinical programs include Phase 2 trials for Parkinson’s and planning for Alzheimer’s.

Who are Ceregene's competitors?

Ceregene's competitors and similar companies include Algynomics, Rapport Therapeutics, Pacira BioSciences, Satsuma Pharmaceuticals, and Neuraxpharm.

Where is Ceregene headquartered?

Ceregene is headquartered in United States.

How many employees does Ceregene have?

Ceregene has 1,000 employees 🔒.

When was Ceregene founded?

Ceregene was founded in 2010 🔒.

What sector and industry vertical is Ceregene in?

Ceregene is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Ceregene

Who are the top strategic acquirers in Ceregene's sector and industry

Top strategic M&A buyers and acquirers in Ceregene's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Ceregene?

Top strategic M&A buyers groups and sectors for Ceregene include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Ceregene's sector and industry vertical

Which are the top PE firms investing in Ceregene's sector and industry vertical?

Top PE firms investing in Ceregene's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Ceregene's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Ceregene's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Ceregene's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Ceregene include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Ceregene's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Ceregene?

The key public trading comparables and valuation benchmarks for Ceregene include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Ceregene for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Ceregene with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Ceregene's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Ceregene with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Ceregene's' sector and industry vertical?

Access recent funding rounds and capital raises in Ceregene's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Ceregene

Start Free Trial Book a Demo